title: Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease.
abstract: The effects of combined atorvastatin and amlodipine on blood pressure (BP) and low-density lipoprotein (LDL) cholesterol levels were investigated in 134 patients with documented coronary heart disease treated for 1 year. BP at baseline was 128 +/- 15/79 +/- 9 mm Hg and was controlled by the treating physician; no calcium channel blockers were allowed. Baseline means for plasma cholesterol were 6.4 +/- 1.1 mmol/L (147 +/- 39 mg/dl), triglycerides 2.0 +/- 0.9 mmol/L (177 +/- 88 mg/dl), LDL cholesterol 4.4 +/- 1.0 mmol/L (170 +/- 39 mg/dl), and high-density lipoprotein cholesterol 1.2 +/- 0.3 mmol/L (46 +/- 12 mg/dl). Patients were all given atorvastatin 10 mg, then increased to 80 mg if the LDL cholesterol was <2.5 mmol/L (100 mg/dl). At 3 months, patients were randomized to amlodipine 10 mg or placebo. Plasma LDL cholesterol was decreased by 50%, and the LDL cholesterol target of <2.5 mmol/L was achieved in 81% of the patients. BP targets were achieved in 69% of the atorvastatin + placebo group, versus 96% in the atorvastatin + amlodipine group (p = 0.0002). With use of combination atorvastatin + amlodipine at doses ranging from 10 to 80 mg and 5 to 10 mg, respectively, recommended therapeutic goals were reached in most select subjects with coronary artery disease who were concomitantly receiving aspirin and antihypertensive therapy.
authors.affiliation: Division of Cardiology, McGill University Health Center, 687 Pine Avenue, Montreal, Québec H3A 1A1, Canada.
authors.forename: Jean-Francois
authors.initials: JF
authors.lastname: Dorval
authors.forename: Todd
authors.initials: T
authors.lastname: Anderson
authors.forename: Jean
authors.initials: J
authors.lastname: Buithieu
authors.forename: Sammy
authors.initials: S
authors.lastname: Chan
authors.forename: Stuart
authors.initials: S
authors.lastname: Hutchison
authors.forename: Thao
authors.initials: T
authors.lastname: Huynh
authors.forename: Jean
authors.initials: J
authors.lastname: Jobin
authors.forename: Eva
authors.initials: E
authors.lastname: Lonn
authors.forename: Paul
authors.initials: P
authors.lastname: Poirier
authors.forename: Lawrence
authors.initials: L
authors.lastname: Title
authors.forename: Ann
authors.initials: A
authors.lastname: Walling
authors.forename: Thang
authors.initials: T
authors.lastname: Tran
authors.forename: Ghyslain
authors.initials: G
authors.lastname: Boudreau
authors.forename: Francois
authors.initials: F
authors.lastname: Charbonneau
authors.forename: Jacques
authors.initials: J
authors.lastname: Genest
mesh_terms: D017311:Amlodipine / Q000008:administration & dosage*; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D000069059:Atorvastatin; D001794:Blood Pressure; D002170:Canada; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000008:administration & dosage*; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: D000959:Antihypertensive Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D014280:Triglycerides; D017311:Amlodipine; D002784:Cholesterol; D000069059:Atorvastatin